

Masaoki Ito

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1099066/publications.pdf>

Version: 2024-02-01

39
papers

668
citations

567247

15
h-index

610883

24
g-index

41
all docs

41
docs citations

41
times ranked

1206
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Behavior of Combined Versus Pure High-Grade Neuroendocrine Carcinoma. <i>Clinical Lung Cancer</i> , 2022, 23, e9-e16.e1.	2.6	2
2	Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pNOMO EGFR-mutant lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1419-1428.	2.5	2
3	Digital multiplexed analysis of circular RNAs in FFPE and fresh non-small cell lung cancer specimens. <i>Molecular Oncology</i> , 2022, 16, 2367-2383.	4.6	10
4	The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1306-1315.e4.	0.8	14
5	Abstract PS19-23: Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer. , 2021, , .		0
6	Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3709-3718.	2.5	8
7	Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer. <i>Breast Cancer</i> , 2021, 28, 1062-1071.	2.9	0
8	Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. <i>British Journal of Cancer</i> , 2021, 125, 1602-1611.	6.4	25
9	Pathological high malignant grade is higher risk of recurrence in pNOMO invasive lung adenocarcinoma, even with small invasive size. <i>Thoracic Cancer</i> , 2021, 12, 3141-3149.	1.9	5
10	Prospective, randomized, cross-over pilot study of the effects of Rikkunshito, a Japanese traditional herbal medicine, on anorexia and plasma-acylated ghrelin levels in lung cancer patients undergoing cisplatin-based chemotherapy. <i>Investigational New Drugs</i> , 2020, 38, 485-492.	2.6	17
11	Intense Expression of EGFR L858R Characterizes the Micropapillary Component and L858R Is Associated with the Risk of Recurrence in pNOMO Lung Adenocarcinoma with the Micropapillary Component. <i>Annals of Surgical Oncology</i> , 2020, 27, 945-955.	1.5	11
12	Neoadjuvant atezolizumab plus chemotherapy in resectable non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2020, 21, 736-738.	10.7	2
13	Positive EGFR mutation status is a risk of recurrence in pNOMO lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis. <i>Lung Cancer</i> , 2020, 141, 107-113.	2.0	33
14	Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100084.	1.1	2
15	Metachronous Lung Cancer After Pleurectomy/Decortication. <i>Annals of Thoracic Surgery</i> , 2019, 107, e1-e3.	1.3	0
16	Characterising acquired resistance to erlotinib in non-small cell lung cancer patients. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1019-1028.	2.5	8
17	Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2325-2333.	2.5	7
18	Targeting PKC δ -PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma. <i>Cell Communication and Signaling</i> , 2019, 17, 137.	6.5	21

#	ARTICLE	IF	CITATIONS
19	Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines. <i>Translational Lung Cancer Research</i> , 2019, 8, 340-351.	2.8	12
20	Breast cancer cell motility is promoted by 14-3-3 β . <i>Breast Cancer</i> , 2019, 26, 581-593.	2.9	15
21	Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma. <i>Oncology Letters</i> , 2019, 17, 3607-3614.	1.8	8
22	Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 167-177.	2.6	37
23	Targeting PKC δ -PAK1 in EGFR-mutation positive non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 667-673.	2.8	11
24	Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC). <i>EBioMedicine</i> , 2019, 39, 207-214.	6.1	38
25	Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, 651-651.	1.7	18
26	STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876374.	3.2	30
27	Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis. <i>EBioMedicine</i> , 2018, 29, 112-127.	6.1	63
28	Postoperative complications and prognosis after lobar resection versus sublobar resection in elderly patients with clinical Stage I non-small-cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 366-371.	1.4	40
29	Management pathways for solitary pulmonary nodules. <i>Journal of Thoracic Disease</i> , 2018, 10, S860-S866.	1.4	12
30	Increased risk of recurrence in resected EGFR-positive pNOMO invasive lung adenocarcinoma. <i>Thoracic Cancer</i> , 2018, 9, 1594-1602.	1.9	19
31	Outcomes after lobar versus sublobar resection for clinical stage I non-small cell lung cancer in patients with interstitial lung disease. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 1089-1096.e1.	0.8	42
32	The combination of checkpoint immunotherapy and targeted therapy in cancer. <i>Annals of Translational Medicine</i> , 2017, 5, 388-388.	1.7	54
33	Therapeutic strategies and genetic profile comparisons in small cell carcinoma and large cell neuroendocrine carcinoma of the lung using next-generation sequencing. <i>Oncotarget</i> , 2017, 8, 108936-108945.	1.8	9
34	Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 51, ezw318.	1.4	10
35	β -Parvin, a pseudopodial constituent, promotes cell motility and is associated with lymph node metastasis of lobular breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 59-69.	2.5	21
36	Prediction for prognosis of resected pT1a-1bNOMO adenocarcinoma based on tumor size and histological status: Relationship of TNM and IASLC/ATS/ERS classifications. <i>Lung Cancer</i> , 2014, 85, 270-275.	2.0	39

#	ARTICLE	IF	CITATIONS
37	Classifications of N2 Non-Small-Cell Lung Cancer Based on the Number and Rate of Metastatic Mediastinal Lymph Nodes. <i>Clinical Lung Cancer</i> , 2013, 14, 651-657.	2.6	14
38	Lung metastasis of adenoid cystic carcinoma, which mimicked primary lung cancer. <i>Thoracic Cancer</i> , 2013, 4, 327-329.	1.9	4
39	Prognostic impact of targetable genetic variants in resected adenocarcinoma of the lung: a narrative review and model proposal for precise evaluation. <i>Precision Cancer Medicine</i> , 0, 3, 19-19.	1.8	2